Literature DB >> 19179637

Projecting future drug expenditures--2009.

James M Hoffman1, Nilay D Shah, Lee C Vermeulen, Fred Doloresco, Patrick K Martin, Sharon Blake, Linda Matusiak, Robert J Hunkler, Glen T Schumock.   

Abstract

PURPOSE: Drug expenditure trends in 2007 and 2008, projected drug expenditures for 2009, and factors likely to influence drug expenditures are discussed.
SUMMARY: Various factors are likely to influence drug expenditures in 2009, including drugs in development, the diffusion of new drugs, drug safety concerns, generic drugs, Medicare Part D, and changes in the drug supply chain. The increasing availability of important generic drugs and drug safety concerns continue to moderate growth in drug expenditures. The drug supply chain remains dynamic and may influence drug expenditures, particularly in specialized therapeutic areas. Initial data suggest that the Medicare Part D benefit has influenced drug expenditures, but the ultimate impact of the benefit on drug expenditures remains unclear. From 2006 to 2007, total U.S. drug expenditures increased by 4.0%, with total spending rising from $276 billion to $287 billion. Drug expenditures in clinics continue to grow more rapidly than in other settings, with a 9.9% increase from 2006 to 2007. Hospital drug expenditures increased at a moderate rate of only 1.6% from 2006 to 2007; through the first nine months of 2008, hospital drug expenditures increased by only 2.8% compared with the same period in 2007.
CONCLUSION: In 2009, we project a 0-2% increase in drug expenditures in outpatient settings, a 1-3% increase in expenditures for clinic-administered drugs, and a 1-3% increase in hospital drug expenditures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179637     DOI: 10.2146/ajhp080636

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  9 in total

1.  Accuracy of annual prescription drug expenditure forecasts in AJHP.

Authors:  Patricia L Hartke; Lee C Vermeulen; James M Hoffman; Nilay D Shah; Fred Doloresco; Katie J Suda; Edward C Li; Linda M Matusiak; Robert J Hunkler; Glen T Schumock
Journal:  Am J Health Syst Pharm       Date:  2015-10-01       Impact factor: 2.637

2.  Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia.

Authors:  George Dranitsaris; Ilse Truter; Martie S Lubbe; Nitin N Sriramanakoppa; Vivian M Mendonca; Sangameshwar B Mahagaonkar
Journal:  Malays J Med Sci       Date:  2011-10

3.  Stability of infliximab in polyvinyl chloride bags.

Authors:  Ryuji Ikeda; Lee C Vermeulen; Elim Lau; Zhisheng Jiang; Sumona Saha; Mark Reichelderfer; Jill M Kolesar
Journal:  Am J Health Syst Pharm       Date:  2012-09-01       Impact factor: 2.637

4.  Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients.

Authors:  Limin Gao; Jivin Joseph; Marcelle Santoro-Levy; Alan S Multz; Vladimir K Gotlieb
Journal:  Hosp Pharm       Date:  2016-07

5.  An Anticancer Drug Unit for the whole provincial oncologic network of Piacenza: improving safety and savings.

Authors:  Patrizia Mordenti; Stefano Vecchia; Enrico Damonti; Alessandra Riva; Monica Muroni; Maria Rosa Cordani; Gabriele Cremona; Luigi Cavanna
Journal:  Med Oncol       Date:  2015-01-09       Impact factor: 3.064

Review 6.  Pro/con debate: Should antimicrobial stewardship programs be adopted universally in the intensive care unit?

Authors:  Philip George; Andrew M Morris
Journal:  Crit Care       Date:  2010-02-25       Impact factor: 9.097

7.  Forecasting drug utilization and expenditure in a metropolitan health region.

Authors:  Björn Wettermark; Marie E Persson; Nils Wilking; Mats Kalin; Seher Korkmaz; Paul Hjemdahl; Brian Godman; Max Petzold; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-05-17       Impact factor: 2.655

8.  Drug waste minimization as an effective strategy of cost-containment in oncology.

Authors:  Gianpiero Fasola; Giuseppe Aprile; Luisa Marini; Alessandro Follador; Mauro Mansutti; Manuela Miscoria
Journal:  BMC Health Serv Res       Date:  2014-02-07       Impact factor: 2.655

9.  Antimicrobial stewardship program (ASP): an effective implementing technique for the therapy efficiency of meropenem and vancomycin antibiotics in Iranian pediatric patients.

Authors:  Aliakbar Rahbarimanesh; Sayed Yousef Mojtahedi; Payman Sadeghi; Maryam Ghodsi; Sara Kianfar; Leila Khedmat; Saeedreza Jamali Moghadam Siyahkali; Mohammad Kaji Yazdi; Anahita Izadi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-01-29       Impact factor: 3.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.